GSK to buy 8.5 percent more of Theravance for $213M

GlaxoSmithKline PLC agreed to buy 10 million shares of Theravance Inc., increasing its stake in the South San Francisco company by 8.5 percent.
Theravance (NASDAQ: THRX) will get $212.9 million gross in this deal, as Glaxo (NYSE: GSK) agreed to pay $21.2887 per share.